Catalyzes the hydrolysis of glycosphingolipids and participates in their degradation in the lysosome. Hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. globoside Gb3Cer (d18:1(4E)) + H2O = a beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-Cer(d18:1(4E)) + D-galactose globoside Gb3Cer + H2O = beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-ceramide + D-galactose Galactosylgalactosylglucosylceramidase activity is stimulated by saposin B and ammonium chloride. Homodimer. Partially edited. The disease is caused by variants affecting the gene represented in this entry. Available under the names Replagal (from Shire) and Fabrazyme (from Genzyme). Used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. The differences between Replagal (also known as agalsidase alpha) and Fabrazyme (also known as agalsidase beta) lies in the glycosylation patterns. Agalsidase beta is produced in the hamster CHO cell line while agalsidase alpha is produced in human cell lines. Belongs to the glycosyl hydrolase 27 family.